Correction for: Efficacy and safety of recombinant human follicle-stimulating hormone in patients undergoing in vitro fertilization-embryo transfer

Affiliations

¹ The First Affiliated Hospital of Zhengzhou University, Reproductive Medicine, Zhengzhou, China.
² Sir Run Run Shaw Hospital of Zhejiang University, Reproductive Medicine, Hangzhou, China.
³ Southern Medical University, Reproductive Medicine, Guangzhou, China.
⁴ Second Affiliated Hospital of Wenzhou Medical University, Reproductive Medicine, Wenzhou, China.
⁵ Peking University Shenzhen Hospital, Reproductive Medicine, Shenzhen, China.
⁶ Hainan Medical College, Reproductive Medicine, Haikou, China.

Published Erratum

Linli Hu et al. Aging (Albany NY). 2023.

. 2023 Jun 29;15(12):5951-5953.

doi: 10.18632/aging.204490. Epub 2023 Jun 29.

¹ The First Affiliated Hospital of Zhengzhou University, Reproductive Medicine, Zhengzhou, China.
² Sir Run Run Shaw Hospital of Zhejiang University, Reproductive Medicine, Hangzhou, China.
³ Southern Medical University, Reproductive Medicine, Guangzhou, China.
⁴ Second Affiliated Hospital of Wenzhou Medical University, Reproductive Medicine, Wenzhou, China.
⁵ Peking University Shenzhen Hospital, Reproductive Medicine, Shenzhen, China.
⁶ Hainan Medical College, Reproductive Medicine, Haikou, China.

No abstract available

Keywords: IVF-ET; assisted reproductive technology (ART); oocytes retrieved; ovarian stimulation; recombinant human FSH (r-hFSH).

Erratum for

Efficacy and safety of recombinant human follicle-stimulating hormone in patients undergoing in vitro fertilization-embryo transfer.
Hu L, Zhang S, Quan S, Lv J, Qian W, Huang Y, Lu W, Sun Y. Hu L, et al. Aging (Albany NY). 2020 Mar 25;12(6):4918-4930. doi: 10.18632/aging.102919. Epub 2020 Mar 25. Aging (Albany NY). 2020. PMID: 32209728 Free PMC article. Clinical Trial.